TABLE 4.

Univariate analysis comparing patients carrying ciprofloxacin-susceptible and -resistant strains of E. coli in the fecal flora (n = 360)

CharacteristicCipros (n = 318)aCipror (n = 42)aORbCIcP valued
Male sex (% of patients)49.747.60.92(0.48-1.75)0.8
Median age (yr)65.972.21.19(0.99-1.44)0.0654
Median Charlson score2.431.13(0.97-1.31)0.1257
Not coming from home (% of patients)21.435.72.04(1.03-4.06)0.0412
Hospitalized in the last year (% of patients)48.752.41.16(0.61-2.2)0.6577
Median number of days since last hospital stay82.2113.71.1(0.96-1.27)0.17
Carriage of MDR bacteria (% of patients)9.140.56.78(3.28-13.99)<0.0001
    MRSA6.6193.12(0.96-6.4)0.08
    ESBL5.730.97.47(3.32-16.78)<0.0001
Antibiotic treatment in the last 3 months (% of patients)44.366.72.51(1.27-4.95)0.0078
    Fluoroquinolone9.8192.18(0.93-5.12)0.0742
    Aminoglycoside5.57.91.48(0.41-5.33)0.55
    β-Lactam35.153.72.14(1.11-4.12)0.023
    Glycopeptide2.57.12.98(0.76-11.71)0.117
Period of antibiotic exposure (% of patients)
    0 days56.233.310.019
    1-7 days26.535.72.27(1.05-4.92)
    >8 days17.4313.01(11.33-6.78)
Period since the end of antibiotic treatment (% of patients)
    0 days58.564.310.848
    1-30 days28.9250.79(0.31-2.04)
    31-90 days12.710.70.77(0.20-2.89)
  • a Cipro, ciprofloxacin. Superscripts indicated resistance (r) and susceptibility (s).

  • b OR, odds ratio.

  • c CI, confidence interval.

  • d Statistically significant values are indicated in boldface (P < 0.05).